Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 51, 2021 - Issue 21
470
Views
23
CrossRef citations to date
0
Altmetric
Articles

New thiazole and thiazole-chromene hybrids possessing morpholine units: Piperazine-mediated one-pot synthesis of potential acetylcholinesterase inhibitors

, ORCID Icon &
Pages 3332-3344 | Received 04 Jun 2021, Published online: 29 Aug 2021
 

Abstract

In the current study, new morpholine-linked thiazoles were prepared by the reaction of salicylaldehyde derivative, thiosemicarbazide, and α-bromoketones. To mediate the previous three-component reaction, the reaction was conducted using two equiv. of piperazine in dioxane at reflux for 5 h. Using the prior protocol, two series of thiazoles, linked to arene or chromene units, were prepared in good to excellent yields. The new thiazoles were examined as potential inhibitors of acetylcholinesterase at a concentration of 50 µM. When compared to donepezil (inhibition percentage of 92.8%), hybrids 11b and 11c, linked to 6-chloro or 6-bromochromen-3-yl units, gave the best inhibition percentages of 72.3 and 71.5%, respectively. Furthermore, when tested at a concentration of 25 µg/mL, the same hybrids demonstrated the highest DPPH antioxidant activity, with inhibition percentages of 84.1 and 83.2%, respectively, when compared to ascorbic acid (inhibition percentage of 89.5%).

Graphical Abstract

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.